• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.海地太子港功能性CYP2B6变体与含依非韦伦方案的病毒学反应
J Antimicrob Chemother. 2014 Aug;69(8):2187-90. doi: 10.1093/jac/dku088. Epub 2014 Apr 2.
2
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.HIV感染的携带CYP2B6慢代谢基因型的成年患者的次生代谢途径多态性与血浆依法韦仑浓度
J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.
3
CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.乌干达接受含依非韦伦抗逆转录病毒治疗方案的成人HIV感染者中CYP2B6基因多态性、抑郁与病毒抑制:两项前瞻性研究的汇总分析
AIDS Res Hum Retroviruses. 2018 Nov;34(11):982-992. doi: 10.1089/AID.2018.0062. Epub 2018 Aug 15.
4
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.海地太子港抗逆转录病毒治疗期间CYP2B6基因变体与血浆依非韦伦浓度
J Infect Dis. 2009 Sep 15;200(6):955-64. doi: 10.1086/605126.
5
Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.简短报告:在博茨瓦纳接受依非韦伦治疗的HIV感染患者中,CYP2B6基因516G>T次要等位基因对晚期病毒学失败具有保护作用。
J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):488-491. doi: 10.1097/QAI.0000000000001442.
6
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.南非成人和儿童HIV感染者血浆依法韦仑暴露的药物遗传学
Br J Clin Pharmacol. 2015 Jul;80(1):146-56. doi: 10.1111/bcp.12590. Epub 2015 May 28.
7
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.CYP2B6、ABCB1 和 CYP3A5 多态性对依非韦伦药代动力学和治疗反应的影响:一项艾滋病临床治疗试验组研究。
J Infect Dis. 2010 Sep 1;202(5):717-22. doi: 10.1086/655470.
8
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.中国 HIV 感染患者 CYP2B6 多态性与非核苷类逆转录酶抑制剂血药浓度。
Ther Drug Monit. 2010 Oct;32(5):573-8. doi: 10.1097/FTD.0b013e3181ea953c.
9
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.重要的种族、CYP2B6 和 ABCB1 基因型对依非韦伦药代动力学和治疗结局的影响:在撒哈拉以南非洲两个人群中进行的平行组前瞻性队列研究。
PLoS One. 2013 Jul 5;8(7):e67946. doi: 10.1371/journal.pone.0067946. Print 2013.
10
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.细胞色素P450 2B6(CYP2B6)基因18492位点的T→C多态性会降低携带CYP2B6单倍型*1/*1的HIV合并结核感染患者体内依非韦伦的血药浓度。
Antimicrob Agents Chemother. 2014;58(4):2268-73. doi: 10.1128/AAC.02384-13. Epub 2014 Feb 3.

引用本文的文献

1
Pharmacogenetics of HIV therapy: State of the art in Latin American countries.艾滋病治疗的药物遗传学:拉丁美洲国家的最新状况
Genet Mol Biol. 2022 Sep 30;45(3 Suppl 1):e20220120. doi: 10.1590/1678-4685-GMB-2022-0120. eCollection 2022.
2
Association of Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.博茨瓦纳HIV-1患者中基因变异与依非韦伦和奈韦拉平耐药性的关联
Pharmgenomics Pers Med. 2021 Mar 16;14:335-347. doi: 10.2147/PGPM.S289471. eCollection 2021.
3
CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.乌干达接受含依非韦伦抗逆转录病毒治疗方案的成人HIV感染者中CYP2B6基因多态性、抑郁与病毒抑制:两项前瞻性研究的汇总分析
AIDS Res Hum Retroviruses. 2018 Nov;34(11):982-992. doi: 10.1089/AID.2018.0062. Epub 2018 Aug 15.
4
CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.博茨瓦纳 CYP2B6 基因型与早期依非韦伦为基础的 HIV 治疗结局。
AIDS. 2017 Sep 24;31(15):2107-2113. doi: 10.1097/QAD.0000000000001593.
5
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.对南非黑人艾滋病毒/艾滋病患者依法韦仑反应的药物遗传学决定因素的扩展分析,其中包括3'-UTR单核苷酸多态性
Front Genet. 2016 Jan 7;6:356. doi: 10.3389/fgene.2015.00356. eCollection 2015.
6
Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.在HIV临床实践中CYP2B6基因分型用于优化依非韦伦剂量的成本效益分析
Pharmacogenomics. 2015 Dec;16(18):2007-18. doi: 10.2217/pgs.15.142. Epub 2015 Nov 26.
7
Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa.南非接受抗逆转录病毒治疗的产后女性中的治疗失败、耐药性及CD4 T细胞计数下降情况
J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):31-7. doi: 10.1097/QAI.0000000000000811.
8
PharmGKB summary: Efavirenz pathway, pharmacokinetics.药物基因组学知识库总结:依非韦伦途径,药代动力学。
Pharmacogenet Genomics. 2015 Jul;25(7):363-76. doi: 10.1097/FPC.0000000000000145.
9
Pharmacogenomics of antimicrobial agents.抗菌药物的药物基因组学
Pharmacogenomics. 2014;15(15):1903-30. doi: 10.2217/pgs.14.147.
10
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.艾滋病临床试验组方案中含依非韦伦或含阿巴卡韦方案的病毒学应答全基因组关联研究。
Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

本文引用的文献

1
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.多种遗传变异可预测柬埔寨 HIV 感染者中奈韦拉平的稳态清除率。
Pharmacogenet Genomics. 2012 Dec;22(12):868-76. doi: 10.1097/FPC.0b013e32835a5af2.
2
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.全基因组关联研究发现 AIDS 临床试验组方案中血浆依非韦伦药代动力学与几个 CYP2B6 变异有关。
Pharmacogenet Genomics. 2012 Dec;22(12):858-67. doi: 10.1097/FPC.0b013e32835a450b.
3
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.抗 HIV 一线治疗药物过早停药与药物遗传学标记物的相关性:一项观察性队列研究。
J Infect Dis. 2011 Jan 15;203(2):246-57. doi: 10.1093/infdis/jiq043. Epub 2010 Dec 9.
4
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.CYP2B6、ABCB1 和 CYP3A5 多态性对依非韦伦药代动力学和治疗反应的影响:一项艾滋病临床治疗试验组研究。
J Infect Dis. 2010 Sep 1;202(5):717-22. doi: 10.1086/655470.
5
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.海地 HIV 感染成人的早期与标准抗逆转录病毒治疗。
N Engl J Med. 2010 Jul 15;363(3):257-65. doi: 10.1056/NEJMoa0910370.
6
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.CYP2B6基因983T>C多态性对HIV感染患者非核苷类逆转录酶抑制剂血浆浓度的影响。
J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.
7
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.细胞色素P450 2B6基因多态性对HIV感染患者中依非韦伦和奈韦拉平的血浆及细胞内浓度和毒性的影响。
Pharmacogenet Genomics. 2005 Jan;15(1):1-5. doi: 10.1097/01213011-200501000-00001.
8
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.依非韦伦的药物遗传学与中枢神经系统副作用:成人艾滋病临床试验组研究
AIDS. 2004 Dec 3;18(18):2391-400.

海地太子港功能性CYP2B6变体与含依非韦伦方案的病毒学反应

Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.

作者信息

Haas David W, Severe Patrice, Jean Juste Marc Antoine, Pape Jean William, Fitzgerald Daniel W

机构信息

Vanderbilt University School of Medicine, Nashville, TN, USA

GHESKIO Centers, Port-au-Prince, Haiti.

出版信息

J Antimicrob Chemother. 2014 Aug;69(8):2187-90. doi: 10.1093/jac/dku088. Epub 2014 Apr 2.

DOI:10.1093/jac/dku088
PMID:24695352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4100704/
Abstract

OBJECTIVES

Efavirenz is widely prescribed for HIV-1 infection. Three polymorphisms in CYP2B6 define plasma efavirenz trough concentration strata that vary across an ∼10-fold range. We characterized associations between human genetic polymorphisms and virologic response among participants who received efavirenz-containing regimens in a prospective clinical trial.

METHODS

We genotyped 76 polymorphisms in CYP2B6 (including those that define efavirenz concentration strata), CYP2A6, CYP3A4, CYP3A5 and ABCB1 and week 48 virologic responses in 360 Haitians who initiated efavirenz-containing regimens in protocol HT 001. Associations were characterized by logistic regression analysis and Fisher's exact test.

RESULTS

Proportions with HIV-1 RNA <50 or <200 copies/mL did not differ across 10 CYP2B6 metabolizer strata. In analyses that combined strata into three metabolizer levels (extensive, intermediate and slow), the respective proportions were 0.79, 0.79 and 0.81 (<50 copies/mL cut-off) and 0.84, 0.86 and 0.87 (<200 copies/mL cut-off). Genetic associations were not identified after controlling for baseline variables or with other polymorphisms after adjusting for multiple comparisons.

CONCLUSIONS

Virologic failures in HT 001 were not explained by genetic polymorphisms known to define the lowest plasma efavirenz concentration stratum.

摘要

目的

依法韦仑被广泛用于治疗HIV-1感染。细胞色素P450 2B6(CYP2B6)基因的三种多态性决定了血浆中依法韦仑谷浓度的分层,其变化范围约为10倍。在一项前瞻性临床试验中,我们对接受含依法韦仑治疗方案的参与者的人类基因多态性与病毒学反应之间的关联进行了特征分析。

方法

我们对参与HT 001方案并开始接受含依法韦仑治疗方案的360名海地人的CYP2B6基因(包括那些决定依法韦仑浓度分层的基因)、CYP2A6、CYP3A4、CYP3A5和ABCB1基因的76种多态性以及第48周的病毒学反应进行了基因分型。通过逻辑回归分析和Fisher精确检验对关联进行特征分析。

结果

在10种CYP2B6代谢型分层中,HIV-1 RNA<50或<200拷贝/毫升的比例没有差异。在将分层合并为三种代谢型水平(快代谢型、中间代谢型和慢代谢型)的分析中,相应比例分别为0.79、0.79和0.81(<50拷贝/毫升临界值)以及0.84、0.86和0.87(<200拷贝/毫升临界值)。在控制基线变量后或在进行多重比较校正后,未发现与其他多态性的基因关联。

结论

HT 001试验中的病毒学失败不能用已知决定最低血浆依法韦仑浓度分层的基因多态性来解释。